Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.
作者信息
Yun Hyun Don, Antony Marie Lue, Linden Michael A, Noble-Orcutt Klara E, Eckfeldt Craig E, Ustun Celalettin, Nelson Andrew C, Sachs Zohar
机构信息
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States; Division of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University, Chicago, IL, United States.
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
出版信息
Leuk Res. 2020 Aug;95:106404. doi: 10.1016/j.leukres.2020.106404. Epub 2020 Jun 11.
Abstract
摘要
相似文献
1
Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.伴有骨髓增生异常综合征的系统性肥大细胞增多症病例中克隆动力学的演变及对靶向治疗的差异反应
Leuk Res. 2020 Aug;95:106404. doi: 10.1016/j.leukres.2020.106404. Epub 2020 Jun 11.
2
MDS with del(5q) and associated cKIT D816V positive mastocytosis.伴有5号染色体长臂缺失（del(5q)）及相关cKIT D816V阳性肥大细胞增多症的骨髓增生异常综合征
Pathology. 2012 Aug;44(5):492-3. doi: 10.1097/PAT.0b013e3283559d03.
3
Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.一名亚洲女性患有KIT K509I突变的高分化系统性肥大细胞增多症并伴有子宫浸润，对伊马替尼反应良好。
Chin Med J (Engl). 2019 Aug 20;132(16):2002-2003. doi: 10.1097/CM9.0000000000000355.
4
Response and progression on midostaurin in advanced systemic mastocytosis: D816V and other molecular markers.中剂量伊马替尼治疗晚期系统性肥大细胞增生症的反应和进展：D816V 及其他分子标志物。
Blood. 2017 Jul 13;130(2):137-145. doi: 10.1182/blood-2017-01-764423. Epub 2017 Apr 19.
5
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.多突变晚期系统性肥大细胞增多症中髓系前体细胞的分子谱分析确定 KIT D816V 为一个独特的晚期事件。
Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.
6
Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review.伴有相关克隆性血液非肥大细胞谱系疾病的系统性肥大细胞增多症：病例回顾
Am J Hematol. 2012 Feb;87(2):191-3. doi: 10.1002/ajh.22208. Epub 2011 Nov 12.
7
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.ASXL1 突变而非 TET2 突变对伴有克隆性血液非肥大细胞疾病的系统性肥大细胞增多症患者的总生存产生不利影响。
PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.
8
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.伴有克隆性血液非肥大细胞系疾病的系统性肥大细胞增生症：SM 和 AHNMD 成分中染色体异常的临床意义和比较。
Am J Hematol. 2013 Mar;88(3):219-24. doi: 10.1002/ajh.23380.
9
Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.使用干扰素-α成功治疗KIT D816V阳性、对伊马替尼耐药的系统性肥大细胞增多症。
Intern Med. 2009;48(22):1973-8. doi: 10.2169/internalmedicine.48.2294. Epub 2009 Nov 16.
10
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.108例成人系统性肥大细胞增多症的减瘤治疗：α干扰素、羟基脲、甲磺酸伊马替尼或2-氯脱氧腺苷治疗期间的疗效分析及反应预测
Am J Hematol. 2009 Dec;84(12):790-4. doi: 10.1002/ajh.21561.
引用本文的文献
1
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.肥大细胞增多症中遗传和获得性基因突变的临床影响。
Int J Mol Sci. 2021 Jan 2;22(1):411. doi: 10.3390/ijms22010411.
本文引用的文献
1
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.CD44 是一种 RAS/STAT5 调节的侵袭受体，可触发晚期肥大细胞增多症中的疾病进展。
Blood. 2018 Nov 1;132(18):1936-1950. doi: 10.1182/blood-2018-02-833582. Epub 2018 Jul 17.
2
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.肥大细胞增多症：2016年世界卫生组织更新分类及新出现的治疗理念。
Blood. 2017 Mar 16;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893. Epub 2016 Dec 28.
3
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.质谱流式细胞术分析揭示骨髓纤维化和继发性急性髓系白血病中NF-κB信号通路的过度激活。
Leukemia. 2017 Sep;31(9):1962-1974. doi: 10.1038/leu.2016.377. Epub 2016 Dec 23.
4
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.高级系统性肥大细胞增多症：从分子和遗传学进展到临床实践。
Haematologica. 2016 Oct;101(10):1133-1143. doi: 10.3324/haematol.2016.146563.
5
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.Stat5对于由Nf1缺陷引发的骨髓增殖性肿瘤的发生和维持至关重要。
Haematologica. 2016 Oct;101(10):1190-1199. doi: 10.3324/haematol.2015.136002. Epub 2016 Jul 14.
6
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.中剂量伊马替尼治疗晚期系统性肥大细胞增多症的疗效和安全性。
N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.
7
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. 在 SRSF2、ASXL1 和/或 RUNX1 中存在额外的突变可确定 KIT D816V(+) 晚期系统性肥大细胞增多症的高危患者群体。
Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14.
8
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.多突变晚期系统性肥大细胞增多症中髓系前体细胞的分子谱分析确定 KIT D816V 为一个独特的晚期事件。
Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.
9
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.TET2突变可预测骨髓增生异常综合征患者对去甲基化药物的反应。
Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.
10
STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.STAT 转录因子在造血和白血病发生中的作用：治疗干预的机会。
Leukemia. 2014 Feb;28(2):248-57. doi: 10.1038/leu.2013.192. Epub 2013 Jun 25.
Zotero 插件